Apple Harvest Cake with Amaretto
Apples are plentiful and delicious, this time of year. ©Joyce Hays, Target Health Inc.
Look at the Amaretto oozing out. ©Joyce Hays, Target Health Inc.
Gather together, all the ingredients. Apple harvest is still going on, so this is the time of year to get out your best apple recipes. This apple cake is one of mine. ©Joyce Hays, Target Health Inc.
4 small apples, washed, halved, peeled and cored (depending on the apple size, you may or may not use all of the apples)
2 Tablespoons fresh lemon juice
2 Tablespoons granulated Splenda
1/4 cup plus 1 Tablespoon unsalted butter, at room temperature
1/4 cup plus 2 Tablespoons (6 tablespoons) granulated Splenda
1/4 cup honey
1 teaspoon vanilla
3 large eggs, separated
2 pinches of Kosher or sea salt
2 teaspoons baking powder
1 and ? cups almond flour
Topping, After Cake Has Cooled (optional)
1/4 cup honey, plus your favorite rum or liqueur
Preheat oven to 350 degrees.
Coat a 9-inch spring-form cake pan with canola spray. Line the bottom of the pan with a round of parchment paper.
Prepare apples: First of all, as you can see in the photo, there are now a plethora of varieties to choose from, so chose your favorite from those locally grown. First I used regular size apples, then I tried a tiny variety, just to fit more apples onto the cake.
Cutting parallel thin apple slices, here, without cutting all the way through the apple. ©Joyce Hays, Target Health Inc.
Place peeled, halved and cored apples cut-side-down on cutting board. With a sharp knife, create parallel thin slices, but only cut halfway through, so each apple half stays together. If you slip and cut through, don’t worry about it. Cut the slices as thin as you can.
In a bowl, toss apples with lemon juice and 2 Tablespoons granulated Splenda.
Prepare cake: With your electric beaters, beat butter and 1/4 cup plus 2 tablespoons granulated Splenda, in a bowl until fluffy. Add honey and beat until combined. Add vanilla and egg yolks, and keep beating until just combined. Slowly, add baking powder and salt to cake batter, and mix briefly for a few seconds, until the batter absorbs everything. Add the almond flour, half at a time, mixing very briefly, until combined.
Clean the beaters and in a separate bowl, beat egg whites until stiff. Stir 1/4 of egg whites into the cake batter. (don’t beat or whip; stir a little and stir very slowly) Fold in the rest, one quarter at a time, three more times. The batter will be stiff, so it will seem impossible to fold into it, but don’t despair, it will gradually loosen up. Fold each addition of egg whites until absorbed. A little bit of white showing is perfectly okay.
Pour the cake batter in your prepared cake pan. Use a spatula to get all the batter into the pan and then to smooth the top of the batter. Arrange (don’t press) the apple halves facedown over the cake batter. If you can only fit 3 or 3 and 1/2 of the apples on top of the batter, that’s fine, no problem. Pour any leftover lemon juice and Splenda, in the bowl, over the apples.
Bake 35 to 40 minutes, until a toothpick comes out clean, after inserting in center of cake. When done, remove cake and rest it on a cooling rack for 5 minutes.
Cut around the cake to make sure it’s not sticking, at all, and unhinge the sides of the spring-form pan. Let cake cool completely. Then, add your rum or Amaretto with a teaspoon, until all of it is completely absorbed. Follow your own taste with this. For us, we love lots of Amaretto, so I literally soak the apple cake in it, until it can hold no more and starts to leak a bit.
This cake can be stored at room temperature for 3 days, after that, store in the fridge.
Before serving, if you want the glaze to look glossy, whenever the cake is cool: Warm 1/4 cup honey and a good pinch of sea salt until it liquefies to the point where it makes a thin glaze – this will take less than 30 seconds. Brush honey-salt mixture over cooled cake. Or, forget about a glaze, your choice. None of my photos show the apple cake with a glaze.
Apple cake for two. ©Joyce Hays, Target Health Inc.
This Apple cake will melt in your mouth. ©Joyce Hays, Target Health Inc.
Have you noticed that sometimes we’re vegan and sometimes paleo? I figure if bears, otters and wolves can be omnivores, so can we humans.
We started out this vegan meal with very fresh mozzarella, sweet grape tomatoes and wine. He wanted white (Cloudy Bay, Sauvignon Blanc, New Zealand) and I had red (Hall, Cabernet Sauvignon, Napa Valley).
Then came the home made Kale/Quinoa Patties with an avocado topping, mashed garlic-y cauliflower with white truffle oil, and fresh sweet baby green garden peas. If I do say so myself, this entr?e was de-lish!
Finally, triumphant, the Apple Cake, literally oozing Amaretto, and was it g-oo-od! With generous dollops of (no-fat) Cool Whip it was truly luscious! Shhhh we had second helpings. J
This was a perfect day starting out at the MetOpera with Marriage of Figaro, one of our favorite operas. We love this opera so much, that years ago when we had to miss a performance of Figaro at the Met, and I happened to notice that a production of Figaro was being done at the Santa Fe Opera House, we decided to fly to Santa Fe, in order not to miss this glorious music.
That was in 1994 or 95, and that was the beginning of our odyssey of the senses, each August, to beautiful Santa Fe, New Mexico, a (tiny) city overflowing with culture and science; a capitol that looks and feels like a friendly village.
Sublime music, like Figaro, really strikes a profound chord in humans. I’m convinced that our five senses (some have six) interact with our intelligence and memory in a way that cannot be duplicated. And this constant interaction is what guides us through life. (Tell that to the robots that are stealing our jobs.)
Hope your weekend was as fulfilling as ours has been!
He wanted white and she toasted with red. ©Joyce Hays, Target Health Inc.
From Our Table to Yours!
Ebola-A Virus Gets a Czar – Time to Take Politics Out of Medicine
Mark L. Horn, MD, MPH, Chief Medical Officer, Target Health Inc.
The appointment of an acknowledged competent political operative, sans scientific and medical credentials but with expertise in operations and knowledge of the political landscape, AKA Ebola Czar reinforces the potential for politicization of the emergence of a small but clearly worrisome number of Ebola infections in the United States. As a physician, while it is not hard to see why the decision was taken, I am concerned that appointment, and the response of politicians with no knowledge of science, medicine and basic facts, has the potential to undermine of the primacy of medical and scientific experts– who ideally should be shepherding the nation through this crisis.
Trust must be earned, and the management of this potential crisis at the beginning, to be charitable, was disappointing. Yet, despite the obvious missteps, so far the only individuals receiving just praise by various authorities have been two frontline nurses who were almost certainly poorly prepared for the tasks they were assigned, yet unselfishly and bravely did their jobs and contracted a potentially lethal disease. They are, to date, together with the frontline healthcare workers in West Africa, two genuine heroines in this evolving story. Their immediate and vigorous support along with the straightforward recommendations for action from nursing leadership rank among the few unequivocal bright lights in the official responses to this crisis.
Many healthcare providers will recall that sometime during their training in medicine and science, they were told never say always, never say never. The obvious point: excessive certainty confers high risk that one will ultimately be proven wrong. With Ebola it didn’t take long. We have discovered yet again that hubris is dangerous, perhaps especially so with an unfamiliar, highly lethal infectious agent.
In tragi-comedic sequence, the projections from the authorities that we want and need to trust, have been proven suspect, from reassurances that the virus would unlikely reach us to repeated assurances that should the unexpected happen, our health care system was prepared, capable of stopping any spread to health care workers and the general public. In addition, specific decisions–e.g. authorizing a known exposed individual to board a commercial flight–were taken that in retrospect appear not merely careless, but reckless. Sadly, these errors are not simply medically and scientifically questionable; they challenge common sense and have therefore alarmed the public.
While it may have been ideal to eliminate politics from this multivariate equation, rapidly moving events have apparently convinced the Administration that a politically sophisticated manager is needed to take control of a deteriorating situation. The administration and the members of the scientific and medical support teams need to establish (or reestablish) their personal credibility, and the credibility of government and its institutions. They must get ahead of the virus, but not ahead of the facts. Uncertainties, challenges, and deficiencies must be frankly acknowledged, capabilities accurately assessed and not overestimated. Spokespersons must show genuine respect for the public which, despite constant exposure to concerning headlines and rhetoric, has displayed remarkable calm. Provided with reliable information offered by trusted leaders, people are far less likely to panic.
It is time for leadership, political, medical and scientific, to step up, acknowledge reality (especially what we don’t know) and implement and communicate proper plans which, importantly, self-evidently err on the side of caution. In short, treat us as adults with much at stake.
As I write this, a case of Ebola has been confirmed in our city. The staff at Bellevue Hospital, where I learned medicine, will be caring for this patient. We hope and trust that they are well prepared and wish them, and their patient, the very best outcome.
Editor’s note: Let us continue our American optimism, and can do approach leading to solutions for significant global crisis, like Ebola. Mistakes will be made. We’re on a learning curve. Here in NYC there is no panic. We know we’lll get through this. Our medical system is the best in the world and we believe in it.
The researchers have not progressed that far yet. Although they have spent the past 20 years developing individual components and prototypes of biological computers, bio-computers today still differ significantly from their counterparts made of silicon, and bio-engineers still face several major obstacles.
A silicon chip, for example, computes with ones and zeros — current is either flowing or not — and it can switch between these states in the blink of an eye. In contrast, biological signals are less clear: in addition to ‘signal’ and ‘no signal’, there is a plethora of intermediate states with ‘a little bit of signal’. This is a particular disadvantage for bio-computer components that serve as sensors for specific biomolecules and transmit the relevant signal. Sometimes, they also send an output signal if no input signal is present, and the problem becomes worse when several such components are connected consecutively in a circuit.
A biosensor that does not ‘leak’
ETH doctoral candidate Nicolas Lapique from the group led by Yaakov Benenson, Professor of Synthetic Biology in the Department of Biosystems Science and Engineering at ETH Zurich in Basel, has now developed a biological circuit that controls the activity of individual sensor components using internal “timer.” This circuit prevents a sensor from being active when not required by the system; when required, it can be activated via a control signal. The researchers recently published their work in the scientific journal Nature Chemical Biology.
To understand the underlying technology, it is important to know that these biological sensors consist of synthetic genes that are read by enzymes and converted into RNA and proteins. In the controllable biosensor developed by Lapique, the gene responsible for the output signal is not active in its basic state, as it is installed in the wrong orientation in the circuit DNA. The gene is activated via a special enzyme, a recombinase, which extracts the gene from the circuit DNA and reinstalls it in the correct orientation, making it active. “The input signals can be transmitted much more accurately than before thanks to the precise control over timing in the circuit,” says Benenson.
To date, the researchers have tested the function of their activation-ready sensor in cell culture of human kidney and cancer cells. Nevertheless, they are already looking ahead to further developing the sensor so that it can be used in a more complex bio-computer that detects and kills cancer cells. These bio-computers will be designed to detect typical cancer molecules. If cancer markers are found in a cell, the circuit could, for example, activate a cellular suicide programme. Healthy cells without cancer markers would remain unaffected by this process.
New signal converter developed
Still, combining various biological components to form more complex bio-computers constitutes a further challenge for bio-engineers. “In electronics, the different components that make up a circuit are always connected in the same way: with a wire through which the current either flows or not,” explains Benenson. In biology, there are a variety of different signals — a host of different proteins or microRNA molecules. In order to combine biologic components in any desired sequence signal converters must be connected between them.
Laura Prochazka, also a doctoral candidate student under Benenson, has developed a versatile signal converter. She published her work recently in the magazine Nature Communications. A special feature of the new component is that not only it converts one signal into another, but it can also be used to convert multiple input signals into multiple output signals in a straightforward manner.
This new biological platform will significantly increase the number of applications for biological circuits. As Benenson says, “The ability to combine biological components at will in a modular, plug-and-play fashion means that we now approach the stage when the concept of programming as we know it from software engineering can be applied to biological computers. Bio-engineers will literally be able to program in future.”
- Nicolas Lapique, Yaakov Benenson. Digital switching in a biosensor circuit via programmable timing of gene availability. Nature Chemical Biology, 2014; DOI:10.1038/nchembio.1680
- Laura Prochazka, Bartolomeo Angelici, Benjamin Haefliger, Yaakov Benenson.Highly modular bow-tie gene circuits with programmable dynamic behaviour.Nature Communications, 2014; 5: 4729 DOI: 10.1038/ncomms5729
ETH Zurich. “Precise, programmable biological circuits.” ScienceDaily. ScienceDaily, 23 October 2014. <www.sciencedaily.com/releases/2014/10/141023100741.htm>.
longstanding question among scientists is whether evolution is predictable. A team of researchers from UC Santa Barbara may have found a preliminary answer. The genetic underpinnings of complex traits in cephalopods may in fact be predictable because they evolved in the same way in two distinct species of squid.
Last, year, UCSB professor Todd Oakley and then-Ph.D. student Sabrina Pankey profiled bioluminescent organs in two species of squid and found that while they evolved separately, they did so in a remarkably similar manner. Their findings are published today in the Proceedings of the National Academy of Science.
Oakley, professor and vice chair of UCSB’s Department of Ecology, Evolution and Marine Biology, and Pankey, now a postdoctoral scholar at the University of New Hampshire, leveraged advances in sequencing technology and cutting-edge genomic tools to test predictability in the evolution of biological light production.
They chose to work with the Hawaiian bobtail squid (Euprymna scolopes) and the swordtip squid (Uroteuthis edulis), a Japanese species used for sushi. These distantly related species are two of five genera known to have bioluminescent organs called photophores. The photophores contain symbiotic, light-emitting bacteria, and the squid are capable of controlling the aperture of their organ to modulate how much light is produced.
The scientists wanted to know how similar the two species’ photophores are in terms of their genetic makeup. To find the answer, they sequenced all of the genes expressed in these light organs, something that could not be done using older sequencing technology.
“They are much more similar than we expected in terms of their genetic makeup,” Oakley said. “Usually when two complicated organs evolve separately we would expect them to take very different evolutionary paths to arrive where they are today. The unexpectedly similar genetic makeup demonstrates that these two squid species took very similar paths to evolve these traits.”
More specifically, the researchers demonstrated that bioluminescent organs originated repeatedly during squid evolution and then showed that the global gene expression profiles (transcriptomes) underlying those organs are strikingly — even predictably — similar. To confirm their hypothesis and findings, Oakley and Pankey enlisted the assistance of statisticians from the University of Washington and UCLA, who developed new statistical methods to test the idea of convergent (separately evolved) origins.
“I did find some individual genes that were counter to the main pattern, which means we can no longer study just one gene anymore in order to test these questions about the genetic basis of convergence,” said Pankey. “We’re at the point now where we need to — and can — study all of them.”
Some previous experiments have indicated that these squid use their bioluminescent capabilities for camouflage, as counterintuitive as that may seem. “If you imagine lying on your back in the deep ocean and looking up, almost all the light comes from straight above,” Oakley explained. “There’s no structure like walls or trees to reflect the light, so if there’s something above you, it’s going to cast a shadow. The squid can produce light that then matches the light from behind them so it blocks their shadow to a viewer below, which is a type of camouflage.”
The team’s results demonstrate that the evolution of overall gene expression underlying convergent complex traits may be predictable. This finding is unexpected and could indicate unusually strong constraints: The probability of complex organs evolving multiple times with similar trajectories should be vanishingly small, noted Oakley. Yet the team’s novel bioinformatic approaches indicate the evolution of convergent phenotypes is associated with the convergent expression of thousands of genes.
“These results have broad implications for workers in the fields of evolution, genetics, genomics/bioinformatics, biomaterials, symbiosis, invertebrate zoology and evolutionary development,” Oakley concluded.
- M. Sabrina Pankey, Vladimir N. Minin, Greg C. Imholte, Marc A. Suchard and Todd H. Oakley. Predictable transcriptome evolution in the convergent and complex bioluminescent organs of squid. PNAS, 2014 DOI:10.1073/pnas.1416574111
University of California – Santa Barbara. “Let there be light: Evolution of complex bioluminescent traits may be predictable.” ScienceDaily. ScienceDaily, 21 October 2014. <www.sciencedaily.com/releases/2014/10/141021135020.htm>.
New research from scientists in the UK and France suggests that human exposure to aluminum may be a significant factor in falling sperm counts and reduced male fertility.
Fluorescence microscopy using an aluminum-specific stain confirmed the presence of aluminum in semen and showed aluminum inside individual sperm.
And the team of scientists, at the universities of Lyon and Saint-Etienne in France and Keele in the UK, found that the higher the aluminum, the lower sperm count.
The research, led by Professor Christopher Exley, a leading authority on human exposure to aluminum at Keele, and Professor Michele Cottier, a specialist in cytology and histology at Saint-Etienne, measured the aluminum content of semen from 62 donors at a French clinic.
Professor Exley said: “There has been a significant decline in male fertility, including sperm count, throughout the developed world over the past several decades and previous research has linked this to environmental factors such as endocrine disruptors.
“Human exposure to aluminum has increased significantly over the same time period and our observation of significant contamination of male semen by aluminum must implicate aluminum as a potential contributor to these changes in reproductive fertility.”
The mean aluminum content for all 62 donors was found to be very high at 339 ppb with the aluminum content of semen from several donors being in excess of 500 ppb. A statistically significant inverse relationship was found between the aluminum content of semen and the sperm count. Higher aluminum resulted in a lower sperm count.
- J.P. Klein, M. Mold, L. Mery, M. Cottier, C. Exley. Aluminium content of human semen: implications for semen quality. Reproductive Toxicology, 2014; DOI:10.1016/j.reprotox.2014.10.001
Keele University. “Exposure to aluminum may impact on male fertility, research suggests.” ScienceDaily. ScienceDaily, 21 October 2014. <www.sciencedaily.com/releases/2014/10/141021085114.htm>.
For those most severely affected, treating epilepsy means drilling through the skull deep into the brain to destroy the small area where the seizures originate — invasive, dangerous and with a long recovery period.
Five years ago, a team of Vanderbilt engineers wondered: Is it possible to address epileptic seizures in a less invasive way? They decided it would be possible. Because the area of the brain involved is the hippocampus, which is located at the bottom of the brain, they could develop a robotic device that pokes through the cheek and enters the brain from underneath which avoids having to drill through the skull and is much closer to the target area.
To do so, however, meant developing a shape-memory alloy needle that can be precisely steered along a curving path and a robotic platform that can operate inside the powerful magnetic field created by an MRI scanner.
The engineers have developed a working prototype, which was unveiled in a live demonstration this week at the Fluid Power Innovation and Research Conference in Nashville by David Comber, the graduate student in mechanical engineering who did much of the design work.
The business end of the device is a 1.14 mm nickel-titanium needle that operates like a mechanical pencil, with concentric tubes, some of which are curved, that allow the tip to follow a curved path into the brain. (Unlike many common metals, nickel-titanium is compatible with MRIs.) Using compressed air, a robotic platform controllably steers and advances the needle segments a millimeter at a time.
According to Comber, they have measured the accuracy of the system in the lab and found that it is better than 1.18 mm, which is considered sufficient for such an operation. In addition, the needle is inserted in tiny, millimeter steps so the surgeon can track its position by taking successive MRI scans.
According to Associate Professor of Mechanical Engineering Eric Barth, who headed the project, the next stage in the surgical robot’s development is testing it with cadavers. He estimates it could be in operating rooms within the next decade.
To come up with the design, the team began with capabilities that they already had. “I’ve done a lot of work in my career on the control of pneumatic systems,” Barth said. “We knew we had this ability to have a robot in the MRI scanner, doing something in a way that other robots could not. Then we thought, ‘What can we do that would have the highest impact?'”
At the same time, Associate Professor of Mechanical Engineering Robert Webster had developed a system of steerable surgical needles. “The idea for this came about when Eric and I were talking in the hallway one day and we figured that his expertise in pneumatics was perfect for the MRI environment and could be combined with the steerable needles I’d been working on,” said Webster.
The engineers identified epilepsy surgery as an ideal, high-impact application through discussions with Associate Professor of Neurological Surgery Joseph Neimat. They learned that currently neuroscientists use the through-the-cheek approach to implant electrodes in the brain to track brain activity and identify the location where the epileptic fits originate. But the straight needles they use can’t reach the source region, so they must drill through the skull and insert the needle used to destroy the misbehaving neurons through the top of the head.
Comber and Barth shadowed Neimat through brain surgeries to understand how their device would work in practice.
“The systems we have now that let us introduce probes into the brain — they deal with straight lines and are only manually guided,” Neimat said. “To have a system with a curved needle and unlimited access would make surgeries minimally invasive. We could do a dramatic surgery with nothing more than a needle stick to the cheek.”
The engineers have designed the system so that much of it can be made using 3-D printing in order to keep the price low. This was achieved by collaborating with Jonathon Slightam and Vito Gervasi at the Milwaukee School of Engineering who specialize in novel applications for additive manufacturing.
Vanderbilt University. “Brain surgery, by robot, through the cheek.” ScienceDaily. ScienceDaily, 15 October 2014.
Target Health – What We Do
ON TARGET is now sent directly to over 5,200 readers each week, by request only and we thank our loyal readers for the very kind words we constantly receive about ON TARGET. Several times a year we dedicate an edition of ON TARGET to Target Health Inc., the parent company of ON TARGET.
Target Health is a New York City-based, full-service, contract research organization (eCRO), providing high level, sophisticated development services to the drug and device industries. Because we have developed software tools to optimize the paperless clinical trial, it is not uncommon for clients to also ask us to provide data management and software product services for projects where the client may be using services of other CRO (e.g. global studies or studies with highly specialized indications). As a result, we are also known as the eCRO for CROs.
View from the 24th Floor Offices of Target Health Inc. © Target Health 2014
The following is a detailed discussion of who we are and what we do.
Innovative Thinking at Target Health
Here are few examples of creative thinking in the development space where Target Health has made a difference:
For the treatment of Gaucher disease, we helped design a program that went from a Phase 1 study in normal volunteers directly to Phase 3. NDA APPROVED
For head lice, we designed the phase 3 study as a placebo controlled, but on the day after the initial treatment, we brought all subjects back and if lice were present, the subject was designated as a treatment failure, but then was retreated, but this time with the active drug. The subject came back the next day, and if lice were not present, the subject continued in the study. This is the standard protocol now for head lice, and we have finished working on our 3rd head lice program. 2 NDAs APPROVED
For a program in emergency contraception, there were delays in enrolling subjects in a study in Europe where the control drug was not approved in the US. We were able to get FDA to agree to expand the study to the US where we studied 2 unapproved drugs. We were able to demonstrate to FDA that the control drug was approved and marketed in Europe, thus there was no resistance to bring the drug into the US for the clinical trial. NDA APPROVED
For a PMA device where from the client’s and our point of view a control was not necessarily needed and could delay implementation of the study, we negotiated with FDA to follow a small number of untreated controls rather than randomize to treatment and no treatment. PMA TO BE SUBMITTED THIS YEAR
Planning the drug and device development process involves broad skills including knowledge of science, medicine, chemistry, toxicology, clinical research and yes, regulatory affairs. Joining Target Health in May 2005, Sr. Director Glen Park, PharmD, now leads the regulatory group that acts as the U.S. Agent for 36 companies at FDA. We advise companies on possible/alternative regulatory pathway and how to optimize time to the market. We have also helped clients on how to communicate with potential licensors.
In recognition of Target Health’s commitment, knowledge and expertise in drug and device development, Dr. Mitchel, President of Target Health, was recently nominated by the Steering Committee of the Clinical Trials Transformation Initiative (CTTI) to be a member its Executive Committee. CTTI is a public/private partnership with FDA and Duke University whose mandate is to transform the way the pharmaceutical and device industries manage and execute clinical trials.
It is all about the data when convincing regulators to approve, physicians to prescribe and for patients, to use a drug or device. Joining Target Health in May 1999, Executive Director Yong Joong Kim now leads our data management team. Whether it is helping clients in the overall data management process, designing Data Management Plans (DMPs), creating industry standard SDTM datasets, making sure that the data make sense or working closely with programing to design EDC application, Yong Joong has developed the best group of DM professionals in the industry. For multiple FDA pre-approval inspections where Target Health performed DM and EDC services, there has never been a finding by FDA inspectors associated with DM.
It is all about our commitment to the paperless trial. Joining Target Health in July 2001, Sr. Director Joonhyuk Choi now leads Target Health’s software development team which is the best in the pharmaceutical industry. Target Health started with traditional electronic data capture (EDC) software (Target e*CRF®) in 1999. Since that time and with multiple NDA, BLA, PMA and EMA approvals, Target Health has made great strides in being the industry leader and advocate for the paperless clinical trial. Flagship products include Target e*Studio®(version 2 of Target e*CRF®), Target eClinical Trial Record (Target e*CTR®; eSource); Target Document® (eTMF); Target Encoder™ (MedDRA and WHODrug coding); Target e*Pharmacovigilance (SAE management) and a development program with Life-on-Key, funded by the BIRD Foundation to integrate any EDC database with any EMR database.
It is all about proving and convincing others that a product actually works. Joining Target Health in August 2002, Director Leigh Ren now leads Target Health’s Biostatistics team which is one of the best in the pharmaceutical industry. Whether we are addressing difficult statistical issues, creating statistical analysis plans (SAPs), running and validating the statistical analyses or writing reports, Leigh’s team can do it all. Supporting Leigh’s team, when necessary, is Dr. Ralph D’Agostino, Jr. Professor of Biostatistics at Wake Forest School of Medicine who has been our statistical consultant since August 1997. A partial list of accomplishments include multiple analyses supporting clinical study reports and the following regulatory approvals: NDA (Gaucher disease, head lice, emergency contraception; infertility); PMA (periodontal disease; adhesion prevention)
It is all about managing the process that shows that a product actually works. Gen Park (2005) runs the clinical research group at Target Health which includes project management, onsite/remote monitoring and medical writing. Clinical programs that have led to approved products include: Gaucher disease, head lice, emergency contraception, periodontal disease and adhesion prevention. One regulatory submission is planned for November of this year and another in Q3 2015, for which full clinical research services have been provided. Current programs include autism, men’s health, rheumatology, and multiple programs in oncology.
For more information about Target Health contact Warren Pearlson (212-681-2100 ext. 104). For additional information about software tools for paperless clinical trials, please also feel free to contact Dr. Jules T. Mitchelor Ms. Joyce Hays. The Target Health software tools are designed to partner with both CROs and Sponsors. Please visit the Target Health Website.
Joyce Hays, Founder and Editor in Chief of On Target
Jules Mitchel, Editor
Cells’ powerhouses were once energy parasites: Study upends current theories of how mitochondria began
Parasitic bacteria were the first cousins of the mitochondria that power cells in animals and plants — and first acted as energy parasites in those cells before becoming beneficial, according to a new University of Virginia study that used next-generation DNA sequencing technologies to decode the genomes of 18 bacteria that are close relatives of mitochondria.
The study appears this week in the online journal PLoS ONE, published by the Public Library of Science. It provides an alternative theory to two current theories of how simple bacterial cells were swallowed up by host cells and ultimately became mitochondria, the “powerhouse” organelles within virtually all eukaryotic cells — animal and plant cells that contain a nucleus and other features. Mitochondria power the cells by providing them with adenosine triphosphate, or ATP, considered by biologists to be the energy currency of life.
The origin of mitochondria began about 2 billion years ago and is one of the seminal events in the evolutionary history of life. However, little is known about the circumstances surrounding its origin, and that question is considered an enigma in modern biology.
“We believe this study has the potential to change the way we think about the event that led to mitochondria,” said U.Va. biologist Martin Wu, the study’s lead author. “We are saying that the current theories — all claiming that the relationship between the bacteria and the host cell at the very beginning of the symbiosis was mutually beneficial — are likely wrong.
“Instead, we believe the relationship likely was antagonistic — that the bacteria were parasitic and only later became beneficial to the host cell by switching the direction of the ATP transport.”
The finding, Wu said, is a new insight into an event in the early history of life on Earth that ultimately led to the diverse eukaryotic life we see today. Without mitochondria to provide energy to the rest of a cell, there could not have evolved such amazing biodiversity, he said.
“We reconstructed the gene content of mitochondrial ancestors, by sequencing DNAs of its close relatives, and we predict it to be a parasite that actually stole energy in the form of ATP from its host — completely opposite to the current role of mitochondria,” Wu said.
In his study, Wu also identified many human genes that are derived from mitochondria — identification of which has the potential to help understand the genetic basis of human mitochondrial dysfunction that may contribute to several diseases, including Alzheimer’s disease, Parkinson’s disease and diabetes, as well as aging-related diseases.
In addition to the basic essential role of mitochondria in the functioning of cells, the DNA of mitochondria is used by scientists for DNA forensics, genealogy and tracing human evolutionary history.
- Zhang Wang, Martin Wu. Phylogenomic Reconstruction Indicates Mitochondrial Ancestor Was an Energy Parasite. PLOS ONE, 2014 DOI:10.1371/journal.pone.0110685
University of Virginia. “Cells’ powerhouses were once energy parasites: Study upends current theories of how mitochondria began.” ScienceDaily. ScienceDaily, 16 October 2014. <www.sciencedaily.com/releases/2014/10/141016165955.htm>.
As medical personnel and public health officials are responding to the first reported cases of Ebola Virus in the United States, many of the safety and treatment procedures for treating the virus and preventing its spread are being reexamined. One of the tenets for minimizing the risk of spreading the disease has been a 21-day quarantine period for individuals who might have been exposed to the virus. But a new study by Charles Haas, PhD, a professor in Drexel’s College of Engineering, suggests that 21 days might not be enough to completely prevent spread of the virus.
Haas’s study “On the Quarantine Period for Ebola Virus,” recently published in PLOS Currents: Outbreaks looks at the murky basis for our knowledge about the virus, namely previous outbreaks in Africa in 1976 (Zaire) and 2000 (Uganda) as well as the first 9 months of the current outbreak.
In both cases, data gathered by the World Health Organization reported a 2-21 day incubation period for the virus -meaning that after 21 days if the individual hasn’t presented symptoms they are likely not to be infected or contagious. This is likely the genesis of the Centers for Disease Control and Prevention’s 21-day quarantine period, but there is little indication from the CDC as to what other considerations played into this policy.
“Twenty-one days has been regarded as the appropriate quarantine period for holding individuals potentially exposed to Ebola Virus to reduce risk of contagion, but there does not appear to be a systemic discussion of the basis for this period,” said Haas, who is the head of the Department of Civil, Architectural and Environmental Engineering at Drexel.
Haas suggests that a broader look at risk factors and costs and benefits should be considered when setting this standard. With any scientific data of this nature there is a standard deviation in results -a percentage by which they may vary. In the case of Ebola’s incubation period the range of results generated from the Zaire and Uganda data varied little. This might have contributed to the health organizations’ certainty that a 21-day quarantine period was a safe course of action.
But looking more broadly at data from other Ebola outbreaks, in Congo in 1995 and recent reports from the outbreak in West Africa, the range of deviation is between 0.1 and 12 percent, according to Haas. This means that there could be up to a 12 percent chance that someone could be infected even after the 21-day quarantine.
“While the 21-day quarantine value, currently used, may have arisen from reasonable interpretation of early outbreak data, this work suggests reconsideration is in order and that 21 days might not be sufficiently protective of public health,” Haas said.
Haas, who has extensive background in analyzing risk of transmitting biological pathogens, explains that these quarantine periods must be determined by looking at the cost of enforcing the quarantine versus the cost of releasing exposed individuals. Looking at the potential tradeoff between costs and benefits as the quarantine time is extended should guide public health officials in determining the appropriate time. Obviously, with more contagious and potentially deadly diseases the cost of making a mistake on the short side when determining a quarantine is extremely high.
“Clearly for pathogens that have a high degree of transmissibility and/or a high degree of severity, the quarantine time should be greater than for agents with lower transmissibility and/or severity. The purpose of this paper is not to estimate where the balancing point should be, but to suggest a method for determining the balancing point.”
- Haas CN. On the Quarantine Period for Ebola Virus. PLOS Currents Outbreaks, 2014 DOI: 10.1371/currents.outbreaks.2ab4b76ba7263ff0f084766e43abbd89
Drexel University. “Study questions 21-day quarantine period for Ebola.” ScienceDaily. ScienceDaily, 15 October 2014. <www.sciencedaily.com/releases/2014/10/141015112323.htm>.
The climate is getting warmer, the ice sheets are melting and sea levels are rising — but how much? The report of the UN’s Intergovernmental Panel on Climate Change (IPCC) in 2013 was based on the best available estimates of future sea levels, but the panel was not able to come up with an upper limit for sea level rise within this century. Now researchers from the Niels Bohr Institute and their colleagues have calculated the risk for a worst-case scenario. The results indicate that at worst, the sea level would rise a maximum of 1.8 meters.
The results are published in the scientific journal Environmental Research Letters.
What causes the sea to rise is when all the water that is now frozen as ice and lies on land melts and flows into the sea. It is first and foremost about the two large, kilometer-thick ice sheets on Greenland and Antarctica, but also mountain glaciers.
In addition, large amounts of groundwater is pumped for both drinking water and agricultural use in many parts of the world and more groundwater is pumped than seeps back down into the ground, so this water also ends up in the oceans.
Finally, what happens is that when the climate gets warmer, the oceans also get warmer and hot water expands and takes up more space. But how much do the experts expect the sea levels to rise during this century at the maximum?
Melting of the ice sheets
“We wanted to try to calculate an upper limit for the rise in sea level and the biggest question is the melting of the ice sheets and how quickly this will happen. The IPCC restricted their projektions to only using results based on models of each process that contributes to sea level. But the greatest uncertainty in assessing the evolution of sea levels is that ice sheet models have only a limited ability to capture the key driving forces in the dynamics of the ice sheets in relation to climatic impact,” Aslak Grinsted, Associate Professor at the Centre for Ice and Climate at the Niels Bohr Institute at the University of Copenhagen.
Aslak Grinsted has therefore, in collaboration with researchers from England and China, worked out new calculations. The researchers have combined the IPCC numbers with published data about the expectations within the ice-sheet expert community for the evolution, including the risk for the collapse of parts of Antarctica and how quickly such a collapse would take place.
“We have created a picture of the propable limits for how much global sea levels will rise in this century. Our calculations show that the seas will likely rise around 80 cm. An increase of more than 180 cm has a likelihood of less than 5 percent. We find that a rise in sea levels of more than 2 meters is improbable,” Aslak Grinsted, but points that the results only concern this century and the sea levels will continue to rise for centuries to come.
- S Jevrejeva, A Grinsted, J C Moore. Upper limit for sea level projections by 2100. Environmental Research Letters, 2014; 9 (10): 104008 DOI: 10.1088/1748-9326/9/10/104008
University of Copenhagen. “Rising sea levels of 1.8 meters in worst-case scenario, researchers calculate.” ScienceDaily. ScienceDaily, 14 October 2014. <www.sciencedaily.com/releases/2014/10/141014085902.htm>.